TrialJAMA oncology2019

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.

Chiara Cremolini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.